Kochañska-Dziurowicz A A, Mielniczuk M R, Stojko A, Kaletka J
Institute of Occupational Medicine and Environmental Health, Department of Radioisotope Clinical Diagnostic, Sosnowiec, Poland.
Br J Urol. 1998 Jun;81(6):834-8. doi: 10.1046/j.1464-410x.1998.00643.x.
To evaluate the role of free-to-total prostate-specific antigen ratio (f/tPSA), prostate volume and PSA density in differentiating between men with prostate cancer and benign prostatic hyperplasia (BPH).
The study comprised 51 patients who were assessed after transurethral electroresection of the prostate (16 with prostate cancer and 35 with BPH). Patients with a tPSA of < or = 4.0 ng/mL and > or = 30.0 ng/mL were excluded from the analysis. Total and fPSA were measured using an immunoradiometric assay and prostate volume was determined by transrectal ultrasonography. The incidence of prostate cancer and BPH was then compared with the PSA variables to determine specificity and predictive value.
Most patients with BPH had a tPSA of 4.0-6.0 ng/mL; no patients with BPH had a tPSA of > 20.0 ng/mL. Most patients with prostate cancer had a f/tPSA of 6-10%. The area under the receiver operating characteristic curve for f/tPSA was significantly greater than that for tPSA (P < 0.003).
The measurement of f/tPSA and PSA density increase the specificity of the differential diagnosis between BPH and prostate cancer.
评估游离前列腺特异性抗原与总前列腺特异性抗原比值（f/tPSA）、前列腺体积及PSA密度在鉴别前列腺癌与良性前列腺增生（BPH）患者中的作用。
本研究纳入51例经尿道前列腺电切术后接受评估的患者（16例前列腺癌患者和35例BPH患者）。tPSA＜或 = 4.0 ng/mL及＞或 = 30.0 ng/mL的患者被排除在分析之外。采用免疫放射分析法测定总PSA和fPSA，并通过经直肠超声检查确定前列腺体积。然后将前列腺癌和BPH的发病率与PSA变量进行比较，以确定特异性和预测价值。
大多数BPH患者的tPSA为4.0 - 6.0 ng/mL；无BPH患者的tPSA＞20.0 ng/mL。大多数前列腺癌患者的f/tPSA为6 - 10%。f/tPSA的受试者工作特征曲线下面积显著大于tPSA（P＜0.003）。
f/tPSA和PSA密度的测定提高了BPH与前列腺癌鉴别诊断的特异性。
Zotero 插件